Combination therapies can address the intractability of cancer and provide a better and promising approach for tumor therapy compared to single-mode therapy. The focus of the current project is the development of the chemical approaches to prepare the Doxorubicin-Poly(2-alkyl-2-oxazoline)s conjugates with a cathepsin cleavable valine-alanine dipeptide linker and proper end-group modification to attaching onto Au NPs and (iron oxide nanoparticle) IONPs, for chemo/radio and chemo/magnetic hyperthermia combination therapies. We are developing two classes of promising all in one anticancer systems, providing: I) enhanced colloidal stability and bio-inertness in physiological media, II) higher drug loading capacity, III) controlled release of drug in the tumor tissue by using enzymatic stimuli- responsive linker, IV) radiosensitizing and ROS generation abilities inside tumor cells, V) heat generating within tumor, and VI) imaging ability. We hypothesize that the novel designed hybrid platforms requirements all of the merits for successful cancer therapy. To achieve the best hybrid formulation in term of stability, safety, radiosensitizing and heat generating abilities as well as anticancer activity under X-Ray irradiation and external radiofrequency electromagnetic field all of the polymers, conjugated polymers, and hybrid systems should be characterized, then biosafety, contrast ability and anticancer activity of them will be evaluated both in vitro and in vivo.